Aptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - For the year ended June 30, revenue is expected to more than double to GBP4.0 million from GBP1.6 million reported the prior 15-month period. Read More
(Alliance News) - The FTSE 100 managed to outperform European counterparts on Friday due to weakness in the pound as consumer confidence in the UK fell to a record low, while attention turns to next week's Jackson Hole Symposium. Read More
(Alliance News) - London's FTSE 100 outperformed peers but was unable to stave off selling pressure in a tough session for European stocks on Friday, despite sitting just above positive territory for much of the late-morning's trade. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said its prostate cancer drug candidate Lynparza has received priority review from the US Food & Drug Administration. Read More
(Alliance News) - Stocks in London struggled on Monday, but managed to end higher, even as China's central bank slashed key interest rates as a raft of data showed weakness in the world's second-largest economy. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said their Enhertu drug met its primary endpoint in a breast cancer trial. Read More
(Alliance News) - Stock prices in London are seen opening higher on Monday, though equities in China were showing signs of late weakness after poorer than expected retail sales data from the world's second-largest economy. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Friday said their drug conjugate Enhertu has been approved for patients in the US with unresectable or metastatic non-small cell lung cancer. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said results from a trial showed promising clinical activity in patients with non-small cell lung cancer. Read More
(Alliance News) - Hutchmed China Ltd and AstraZeneca PLC on Monday said preliminary results from the Savannah phase 2 trial showed a promising objective response rate, and has moved the drug into phase 3 trials. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said their drug conjugate Enhertu has been approved for more patients in the US. Read More
AstraZeneca PLC - Cambridge, England-based pharmaceutical firm - Says new tablet formulation of Calquence, whose generic name is acalabrutinib, has been approved in the US for all current indications. These include adult patients with chronic lymphocytic leukaemia, the most prevalent type of leukaemia in adults, and with blood cancer small lymphocytic lymphoma; and for patients with relapsed or refractory mantle cell lymphoma, an uncommon subtype of B-cell non-Hodgkin lymphoma. AstraZeneca says the approval by the US Food & Drug Administration was based on the Elevate-Plus trials, conducted in 116 healthy subjects. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday: Read More
(Alliance News) - AstraZeneca PLC said on Thursday that Lynparza, which was co-developed with Merck & Co Inc, has received approval in the EU for early high-risk breast cancer, triggering a milestone payment from its collaborator. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday: Read More
(Alliance News) - Stock prices in London were higher on Friday with deteriorating economies prompting expectations for interest rate hikes to be scaled back, as an action-packed week of company and economic news draws to a close. Read More
(Alliance News) - Stock prices in London opened higher on Friday amid hopes the US Federal Reserve will pump the brakes on aggressive rate hikes, while banks boosted the FTSE 100 with the sector awash in cash. Read More
(Alliance News) - AstraZeneca PLC on Friday said it delivered a strong first-half, boosted by demand for its cancer treatments, and lifted its full-year revenue guidance. Read More
(Alliance News) - AstraZeneca on Friday said it delivered a strong first-half boosted by demand for its cancer treatments. Read More
(Alliance News) - Stock prices in London are seen opening higher on Friday on speculation that the Federal Reserve will slow its pace of interest rate hikes after the US economy contracted for two straight quarters. Read More